C5VP001A
Cellicon® Filter Assembly with Durapore® Membrane
filtration area 0.01 m2
Synonym(s):
Cellicon® Perfusion Filter with Durapore® Membrane
Select a Size
About This Item
Quality Level
material
PET support, PVDF , polyester support
agency
meets USP Biological Reactivity Test for class VI plastics (family component materials)
sterility
sterile; γ-irradiated (level of 25-40kGy)
flow rate measuring range
10 L/min (/m2)
parameter
1 psi max. reverse press. exposure at 25 °C, 1-2.5 L process volume, 15 psi at 25 °C (max. burst pressure), 5 psi max. inlet pressure at 25 °C
filtration area
0.01 m2
membrane filtration area
0.01 m2
pore size
5 μm pore size
storage temp.
15-25°C
General description
Application
Seed Train Perfusion
Features and Benefits
Other Notes
Legal Information
Still not finding the right product?
Explore all of our products under Cellicon® Filter Assembly with Durapore® Membrane
Regulatory Information
This item has
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Articles
How the Cellicon® filter and controller enables seamless adoption of a perfused N-1 seed train step into the cell expansion process.
Before adoption of single-use technologies in biomanufacturing, manufacturers must assess the risk to the drug product from potential leachables. This article highlights a general approach based on the United States Pharmacopeia (USP).
Cellvento 4CHO-X Expansion Medium enhances cell biomass for bioreactor inoculation in cell expansion stages.
Related Content
Biopharmaceutical developers need efficient, productive upstream processes that deliver high quality monoclonal antibodies (mAbs) and other types of recombinant proteins. Process intensification can future-proof their manufacturing strategies, reduce costs, and increase facility flexibility.
生物制药开发商需要高效、高产的上游工艺来提供优质的单克隆抗体(mAb)和其他类型重组蛋白。工艺强化可确保生产策略适应未来发展需求、降低成本并提升设施灵活性。
通过我们的细胞截留解决方案提升灌流种子培养效率。实时监测和控制。